Archives: Agenda

• Overcoming site readiness challenges through targeted education, certification, and operational support, ensuring sites are equipped and committed from day one
• Competing smarter in a crowded oncology landscape by making your trial more attractive to sites through simplified protocols, better support, and stronger partnerships
• Moving beyond traditional site selection to identify truly trial-ready sites, assessing infrastructure, staff capacity, competing studies, and long-term engagement potential
• Redefining sponsor–site collaboration with more flexible, locally informed strategies that prioritize feasibility, performance, and sustainable site relationships
• Addressing the growing divide between academic and community sites, and unlocking new models to expand access, improve recruitment, and reduce site drop-off

• Identifying major bottlenecks across the clinical development lifecycle
• Applying regulatory-aligned strategies that shorten timelines without compromising quality
• Integrating data, technology, and cross-functional operating models to streamline execution
• Optimizing interactions with global regulatory agencies for accelerated pathways
• Designing adaptive, patient-centric, and data-efficient clinical trials

With a disproportionately large number of patients willing to participate in global studies, Canada’s world-class researchers and diverse patient population, trial cost efficiency, robust health authority with reliable process times, consistent data quality, and national therapeutic expertise in oncology make it an attractive country for enrollment to your global clinical trial program. This presentation explores how to succeed with your oncology trial in Canada with insights on:

• The Perception Gap
• How Sponsors Receive: Predictability. Speed. Quality. Partner Accountability
• Competitive Structural Advantages
• Real-World Global Trial Examples
• What to Expect in a Partner for the Region

• Building an operating model that aligns sponsors, CROs, and clinical sites around shared timelines and delivery expectations
• Operational strategies for condensing early-phase development timelines while maintaining trial quality and oversight
• Cellectar Biosciences case study: Lessons from a COO on partnering with CROs and clinical sites to rapidly execute studies and meet key clinical milestones
• Managing operational complexity when multiple partners support a single oncology program

• How to choose fit-for-purpose endpoints in modern trial design
• When digital endpoints add value, and why many trials still avoid them
• Differences in decision-making and risk tolerance: large pharma vs. biotech
• Managing complexity through outsourcing: letting vendors do the heavy lifting while you focus on the data
• Keeping scientific and data ownership while external partners handle execution
• Practical lessons from real-world trial designs: what worked and what didn’t